Glaxosmithkline Pharmaceuticals Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 11, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2162 as of 11 Jun 10:25 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 37.3 on March 2026 . This represents a CAGR of -9.55% over 6 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 38682 crore on March 2026 . This represents a CAGR of 7.98% over 6 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Supriya Lifescience Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Supriya Lifescience Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Supriya Lifescience Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 95.44 % on March 2026 . This represents a CAGR of -6.42% over 6 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' in 1987 and was again changed to 'GlaxoSmithKline Pharmaceuticals Limited' dated October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is the Indian subsidiary of GSK plc, a UK-based, science-led global healthcare organisation focused on uniting science, technology and talent to get ahead of disease.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Supriya Lifescience Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 36,833 Cr while Market cap of Supriya Lifescience Ltd is 7,665 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Supriya Lifescience Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Supriya Lifescience Ltd?

As of June 11, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2174.3. On the other hand, Supriya Lifescience Ltd stock price is INR ₹952.45.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.